Business Context and Reporting Period
Company: ORIC Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: May 4, 2026
Reporting Period: Fiscal quarter ended March 31, 2026
Context: The Company issued a press release announcing financial results for the quarter ended March 31, 2026, incorporated by reference as Exhibit 99.1.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) but does not contain specific numerical data. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for this information.
Guidance, Outlook, and Risks
Guidance and Outlook: The filing text does not contain specific forward-looking statements, guidance, or management commentary regarding future performance.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Unusual Items: No unusual items are described in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 4, 2026) for actual financial figures, as they are not included in the 8-K body text.
- Verify the specific revenue, net loss, and cash burn rate for the quarter ended March 31, 2026, in the referenced press release.
- Check for any updated clinical trial milestones or regulatory developments mentioned in the press release.
- Confirm the Company's cash runway and liquidity position as disclosed in the full press release.